Skip to main content
Fig. 5 | Respiratory Research

Fig. 5

From: Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD

Fig. 5

Proportion of patients achieving ≥12 % improvement in FEV1 on Day 1 (mITT population). Treatment difference versus placebo: *p < 0.05; **p < 0.01; ***p < 0.0001. Treatment difference versus open-label tiotropium: p < 0.01; †† p < 0.001; ††† p < 0.0001. Estimated percentages, differences between percentages, and p-values were based on a logistic regression model with achievement of ≥12 % improvement in FEV1 as binary response and the following factors in the model: baseline FEV1, bronchodilator reversibility at Screening, period, and treatment. Exchangeable correlation between responses of the same subject at different periods was assumed. FEV 1 forced expiratory volume in 1 s; GP glycopyrrolate; MDI metered dose inhaler; mITT modified intent-to-treat

Back to article page